, Proc. Natl Acad. Sci. USA, vol.101, pp.14631-14638, 2004.
, A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
, J. Exp. Med, vol.180, issue.1, pp.35-42, 1994.
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc. Natl Acad. Sci. USA, vol.91, issue.9, pp.3515-3519, 1994. ,
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas ,
, J. Exp. Med, vol.178, issue.2, pp.489-495, 1993.
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumorinfiltrating lymphocytes, J. Exp. Med, vol.179, issue.3, pp.1005-1009, 1994. ,
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur. J. Immunol, vol.40, issue.6, pp.1786-1794, 2010. ,
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor, Trends Immunol, vol.23, issue.7, pp.325-328, 2002. ,
Thymic selection generates a large T cell pool recognizing a self-peptide in humans, J. Exp. Med, vol.195, issue.4, pp.485-494, 2002. ,
Tumor-specific and HLA-A2-restricted cytolysis by tumorassociated lymphocytes in human metastatic breast cancer, J. Immunol, vol.155, issue.9, pp.4486-4491, 1995. ,
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, vol.6, issue.2, pp.199-208, 1997. ,
Detection and functional analysis of CD8 + T cells specific for PRAME: a target for T-cell therapy, Clin. Cancer Res, vol.12, issue.10, pp.3130-3136, 2006. ,
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia, Blood, vol.112, issue.5, pp.1876-1885, 2008. ,
Ex vivo characterization of polyclonal memory CD8 + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia, Blood, vol.113, issue.10, pp.2245-2255, 2009. ,
Phase I study of adoptive T-cell therapy using antigen-specific CD8 + T cells for the treatment of patients with metastatic melanoma, J. Clin. Oncol, vol.24, issue.31, pp.5060-5069, 2006. ,
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J. Immunol, vol.170, issue.4, pp.2161-2169, 2003. ,
Adoptive transfer of cloned melanomareactive T lymphocytes for the treatment of patients with metastatic melanoma ,
, J. Immunother, vol.24, issue.4, pp.363-373, 2001.
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones, J. Invest. Dermatol, vol.129, issue.12, pp.2835-2842, 2009. ,
Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc. Natl Acad. Sci. USA, vol.99, issue.25, pp.16168-16173, 2002. ,
A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma, J. Immunother, vol.25, issue.3, pp.243-251, 2002. ,
Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion?, Immunol. Today, vol.18, issue.9, pp.450-454, 1997. ,
Adoptive immunotherapy for cancer: building on success, Nat. Rev. Immunol, vol.6, issue.5, pp.383-393, 2006. ,
Programming CD8 + T cells for effective immunotherapy, Curr. Opin. Immunol, vol.18, issue.3, pp.363-370, 2006. ,
,
, J. Immunol, vol.177, issue.6, pp.3657-3668, 2006.
T-cell-receptor gene therapy, Nat. Rev. Immunol, vol.2, issue.7, pp.512-519, 2002. ,
Transfer of specificity by murine a and b T-cell receptor genes, Nature, vol.320, issue.6059, pp.232-238, 1986. ,
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity, J. Immunol, vol.1163, issue.1, pp.507-513, 1999. ,
Retargeting of a T cell line by anti MAGE-3/HLA-A2 a b TCR gene transfer ,
, Anticancer Res, vol.20, issue.3A, pp.1793-1799, 2000.
Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the a b TCR complex, J. Immunol, vol.165, issue.1, pp.528-532, 2000. ,
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer, Nat. Immunol, vol.2, issue.10, pp.962-970, 2001. ,
Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006. ,
, nn First clinical study reporting the adoptive cell transfer of autologous PBL transduced with an allogeneic T-cell receptor gene, in metastatic melanoma patients
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond, Cancer Res, vol.67, issue.8, pp.3898-3903, 2007. ,
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability, Cancer Res, vol.66, issue.17, pp.8878-8886, 2006. ,
Facilitating matched pairing and expression of TCR chains introduced into human T cells, Blood, vol.109, issue.6, pp.2331-2338, 2007. ,
Selected murine residues endow human TCR with enhanced tumor recognition, J. Immunol, vol.184, issue.11, pp.6232-6241, 2010. ,
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer, J. Immunol, vol.186, issue.2, pp.685-696, 2011. ,
Tumor-specific T bodies: towards clinical application, Cancer Immunol. Immunother, vol.45, issue.3-4, pp.131-136, 1997. ,
Redirecting T-cell specificity by introducing a tumorspecific chimeric antigen receptor, Blood, vol.116, issue.7, pp.1035-1044, 2010. ,
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers, J. Exp. Med, vol.202, issue.3, pp.379-386, 2005. ,
Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med, vol.6, issue.6, pp.707-710, 2000. ,
, Describes an efficient method to sort antigen-specific T cells, based on a3-mutated HLA-A2 multimers coated on magnetic beads
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting, Cancer Immunol. Immunother, vol.57, issue.2, pp.185-195, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00167752
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes, Cancer Immunol. Immunother, vol.58, issue.4, pp.553-566, 2009. ,
Antigen-specific CD4 + T-cell help is required to activate a memory CD8 + T cell to a fully functional tumor killer cell, Cancer Res, vol.62, issue.22, pp.6438-6441, 2002. ,
Divergent roles for CD4 + T cells in the priming and effector/memory phases of adoptive immunotherapy, J. Immunol, vol.165, issue.8, pp.4246-4253, 2000. ,
The central role of CD4 + T cells in the antitumor immune response, J. Exp. Med, vol.188, issue.12, pp.2357-2368, 1998. ,
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes, J. Exp. Med, vol.155, issue.3, pp.768-782, 1982. ,
Cooperation between CD4 + and CD8 + T cells: when, where, and how, Annu. Rev. Immunol, pp.24519-540, 2006. ,
CD4 T cells and their role in antitumor immune responses, J. Exp. Med, vol.189, issue.5, pp.753-756, 1999. ,
Bystander killing of cancer requires the cooperation of CD4 + and CD8 + T cells during the effector phase, J. Exp. Med, vol.207, issue.11, pp.2469-2477, 2010. ,
Tumor-reactive CD4 + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, J. Exp. Med, vol.207, issue.3, pp.637-650, 2010. ,
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy, Annu. Rev. Immunol, pp.19565-594, 2001. ,
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4, J. Clin. Oncol, vol.23, issue.25, pp.6043-6053, 2005. ,
Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma, J. Clin. Oncol, vol.23, issue.4, pp.741-750, 2005. ,
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression, Expert Opin. Biol. Ther, vol.10, issue.7, pp.1019-1035, 2010. ,
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma, J. Immunother, vol.31, issue.4, pp.402-412, 2008. ,
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells, J. Exp. Med, vol.204, issue.1, pp.49-55, 2007. ,
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824, Cancer Res, vol.69, issue.22, pp.8693-8699, 2009. ,